



IBA Lifesciences GmbH
Rudolf-Wissell-Str. 28
37079 Goettingen
Germany
Tel.: +49 (0) 551-5 06 72-0
E-mail: info@iba-lifesciences.com
www.iba-lifesciences.com

Data Sheet

HIV p24-Gag peptide KAFSPEVIPMF

Cat. No.: 6-7071-901

Version: 4.1
Revision Date: 28.09.2021

| | |
|-----------------------|---|
| Description | Single peptide (KAFSPEVIPMF) for stimulation of human HIV p24-Gag₍₃₀₋₄₀₎ -specific CD8 ⁺ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*5701 allele. |
| Form | Lyophilized powder Please spin down briefly before opening the vial. |
| Amount | 1 mg |
| Purity | > 85%, endotoxin free; peptides were purified by HPLC using a water and acetonitrile gradient |
| Stability | 12 months after shipping |
| Storage | Recommended: -25 °C – -15 °C |
| Shipping | Room temperature or frozen |
| Hazards | Product is not classified as hazardous according to (EC) No 1272/2008 [CLP]. A Material Safety Data Sheet is provided. |
| Reconstitution | Peptide solubility depends on amino acid sequence and modifications. For dissolving peptides, we recommend the following: <ul style="list-style-type: none">• Sonication will increase solubility.• 10% acetic acid in the solvent will facilitate dissolving basic peptides.• 10% ammonium bicarbonate will facilitate dissolving acidic peptides.• For peptides with extremely low solubility in aqueous solutions, organic solvents (such as DMSO, isopropanol, methanol, and acetonitrile) should be used first. Once the peptides are completely dissolved, water may be gradually added until the desired concentration is obtained. |

For research use only

Trademark information

The owners of trademarks marked by “®” or “TM” are identified at <http://www.iba-lifesciences.com/patents.html>. Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.